This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodeberg, D. A. Articles by Celis, E. Search for Related Content PubMed PubMed Citation Articles by Rodeberg, D. A. Articles by Celis, E.

Recognition of Six-Transmembrane Epithelial Antigen of the Prostate–Expressing Tumor Cells by Peptide Antigen–Induced Cytotoxic T Lymphocytes

Authors' Affiliation: Department of Immunology, Mayo Clinic College of Medicine, Rochester, Minnesota

Requests for reprints: David A. Rodeberg, Mayo Clinic, 200 First Street, SW Rochester, MN 55905. Phone: 507-284-8391; Fax: 507-284-0058; E-mail: rodeberg.david{at}mayo.edu.

The identification of novel markers and therapeutic targets in advanced cancer is critical for improving diagnosis and therapy. Six-transmembrane epithelial antigen of the prostate (STEAP) is expressed predominantly in human prostate tissue and in other common malignancies including prostate, bladder, colon, and ovarian carcinomas, and in Ewing's sarcoma, suggesting that it could function as an almost universal tumor antigen. We have used MHC peptide binding algorithms to predict potential STEAP sequences capable of stimulating in vitro naïve HLA-A2–restricted CTLs. Four of six peptides predicted by these algorithms were able to induce antigen-specific CTLs that killed peptide-pulsed HLA-A2 target cells. Two of these peptides, STEAP-292 (MIAVFLPIV) and a modification of this peptide STEAP-292.2L (MLAVFLPIV), were the most efficient in the induction of primary CTL responses. More importantly, these CTLs were able to respond to tumor cells that express HLA-A2 and STEAP (colon, bladder, prostate, Ewing's sarcoma, and melanoma). Our results provide strong evidence that STEAP-292 is naturally processed by many tumor types and is presented in the context of HLA-A2 in sufficient amounts to allow recognition by CTLs. Also because STEAP-292.2L is a more immunogenic peptide able to induce CTL recognition of these STEAP-containing tumors and may have potential as an antitumor peptide vaccine.

Key Words: Immunotherapy • cancer vaccine • sarcoma • melanoma

This article has been cited by other articles:

				I. Y. Cheung, Y. Feng, K. Danis, N. Shukla, P. Meyers, M. Ladanyi, and N.-K. V. Cheung Novel Markers of Subclinical Disease for Ewing Family Tumors from Gene Expression Profiling Clin. Cancer Res., December 1, 2007; 13(23): 6978 - 6983. [Abstract] [Full Text] [PDF]

				P. M. Challita-Eid, K. Morrison, S. Etessami, Z. An, K. J. Morrison, J. J. Perez-Villar, A. B. Raitano, X.-C. Jia, J. M. Gudas, S. B. Kanner, et al. Monoclonal Antibodies to Six-Transmembrane Epithelial Antigen of the Prostate-1 Inhibit Intercellular Communication In vitro and Growth of Human Tumor Xenografts In vivo Cancer Res., June 15, 2007; 67(12): 5798 - 5805. [Abstract] [Full Text] [PDF]

				H. Kobayashi, T. Nagato, K. Sato, N. Aoki, S. Kimura, M. Murakami, H. Iizuka, M. Azumi, H. Kakizaki, M. Tateno, et al. Recognition of Prostate and Melanoma Tumor Cells by Six-Transmembrane Epithelial Antigen of Prostate-Specific Helper T Lymphocytes in a Human Leukocyte Antigen Class II-Restricted Manner Cancer Res., June 1, 2007; 67(11): 5498 - 5504. [Abstract] [Full Text] [PDF]

				M. d. l. L. Garcia-Hernandez, A. Gray, B. Hubby, and W. M. Kast In vivo Effects of Vaccination with Six-Transmembrane Epithelial Antigen of the Prostate: A Candidate Antigen for Treating Prostate Cancer Cancer Res., February 1, 2007; 67(3): 1344 - 1351. [Abstract] [Full Text] [PDF]